CN105358532B - 杂环化合物和它们的使用方法 - Google Patents

杂环化合物和它们的使用方法 Download PDF

Info

Publication number
CN105358532B
CN105358532B CN201480038866.XA CN201480038866A CN105358532B CN 105358532 B CN105358532 B CN 105358532B CN 201480038866 A CN201480038866 A CN 201480038866A CN 105358532 B CN105358532 B CN 105358532B
Authority
CN
China
Prior art keywords
compound
alkyl
pain
nhc
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480038866.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105358532A (zh
Inventor
T·D·麦卡锡
A·内勒尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013902513A external-priority patent/AU2013902513A0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN105358532A publication Critical patent/CN105358532A/zh
Application granted granted Critical
Publication of CN105358532B publication Critical patent/CN105358532B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201480038866.XA 2013-07-08 2014-07-08 杂环化合物和它们的使用方法 Expired - Fee Related CN105358532B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013902513 2013-07-08
AU2013902513A AU2013902513A0 (en) 2013-07-08 Method of treatment or prophylaxis
PCT/AU2014/050116 WO2015003223A1 (en) 2013-07-08 2014-07-08 Heterocyclic compounds and methods of their use

Publications (2)

Publication Number Publication Date
CN105358532A CN105358532A (zh) 2016-02-24
CN105358532B true CN105358532B (zh) 2019-07-23

Family

ID=52279233

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480038866.XA Expired - Fee Related CN105358532B (zh) 2013-07-08 2014-07-08 杂环化合物和它们的使用方法

Country Status (9)

Country Link
US (1) US9714224B2 (enExample)
EP (1) EP3019477B1 (enExample)
JP (1) JP6505682B2 (enExample)
CN (1) CN105358532B (enExample)
ES (1) ES2883155T3 (enExample)
NZ (1) NZ630908A (enExample)
PL (1) PL3019477T3 (enExample)
PT (1) PT3019477T (enExample)
WO (1) WO2015003223A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6232384B2 (ja) 2012-01-06 2017-11-15 ノバルティス アーゲー 複素環式化合物およびその使用方法
ES2898635T3 (es) * 2015-03-12 2022-03-08 Novartis Ag Compuestos heterocíclicos y métodos para su uso
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
KR102132761B1 (ko) * 2017-06-09 2020-07-17 산동 단홍 파머수티컬 컴퍼니., 리미티드. At2r 수용체 길항제로서의 카르복시산 유도체
US11485725B2 (en) 2017-12-15 2022-11-01 Auransa Inc. Derivatives of piperlongumine and uses thereof
US11384097B2 (en) 2018-06-19 2022-07-12 Zhejiang Hisun Pharmaceutical Co., Ltd. Tetrahydroisoquinoline derivative, preparation method therefor and use thereof
WO2020012266A1 (en) * 2018-07-12 2020-01-16 Novartis Ag Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase
WO2020228436A1 (zh) 2019-05-10 2020-11-19 浙江海正药业股份有限公司 芳环或杂芳环类衍生物及其制备方法和用途
CN111620816B (zh) * 2020-05-27 2023-06-02 上海赛默罗生物科技有限公司 螺桨烷类衍生物、其制备方法、药物组合物和用途
CN113880825B (zh) * 2020-07-01 2025-03-14 浙江海正药业股份有限公司 四氢异喹啉类衍生物的盐、其制备方法及其医药应用
CN111777555B (zh) * 2020-09-04 2020-12-01 上海赛默罗生物科技有限公司 脂肪环烷衍生物、其制备方法、药物组合物和其应用
AU2022318349B2 (en) 2021-07-30 2025-12-18 Confo Therapeutics N.V. Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling
CN117603088A (zh) * 2023-10-28 2024-02-27 广东工业大学 一种基于氨基酸乙酯的芳香醛席夫碱及其在不对称烷基化中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
WO2003041641A2 (en) * 2001-11-09 2003-05-22 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
WO2006055951A2 (en) * 2004-11-19 2006-05-26 Portola Pharmaceuticals, Inc. Tetrahydroisoquinolines as factor xa inhibitors
CN101443001A (zh) * 2006-03-20 2009-05-27 昆士兰大学 治疗或预防炎性痛的方法
CN102821765A (zh) * 2010-01-19 2012-12-12 西芬克斯医药有限公司 改良神经传导速度的方法和组合物
CN103003244A (zh) * 2010-07-21 2013-03-27 西芬克斯医药有限公司 四氢异喹啉衍生物的盐和溶剂合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55127373A (en) * 1979-03-26 1980-10-02 Takeda Chem Ind Ltd Tetrahydroisoquinoline compound and its preparation
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
JP6232384B2 (ja) 2012-01-06 2017-11-15 ノバルティス アーゲー 複素環式化合物およびその使用方法
JP6258867B2 (ja) 2012-01-25 2018-01-10 ノバルティス アーゲー 複素環式化合物およびその使用方法
EP2807171B1 (en) 2012-01-25 2020-08-12 Novartis AG Heterocyclic compounds and methods for their use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
WO2003041641A2 (en) * 2001-11-09 2003-05-22 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
WO2006055951A2 (en) * 2004-11-19 2006-05-26 Portola Pharmaceuticals, Inc. Tetrahydroisoquinolines as factor xa inhibitors
CN101443001A (zh) * 2006-03-20 2009-05-27 昆士兰大学 治疗或预防炎性痛的方法
CN102821765A (zh) * 2010-01-19 2012-12-12 西芬克斯医药有限公司 改良神经传导速度的方法和组合物
CN103003244A (zh) * 2010-07-21 2013-03-27 西芬克斯医药有限公司 四氢异喹啉衍生物的盐和溶剂合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A Novel Series of Selective, Non-Peptide Inhibitors of Angiotensin I1 Binding to the AT2 Site;Mary K. VanAtten, et al;《Journal of Medicinal Chemistry》;19931210;第36卷(第25期);第3985-3992页，第3988页表1 *
Tetrahydroisoquinoline Derivatives With AT2-Specific Angiotensin II Receptor Binding Inhibitory Activity;Sylvester Klutchko, et al;《Bioorganic & Medicinal Chemistry Letters》;19940106;第4卷(第1期);第57-62页，第59-60页表2 *

Also Published As

Publication number Publication date
US9714224B2 (en) 2017-07-25
EP3019477B1 (en) 2021-05-26
ES2883155T3 (es) 2021-12-07
JP2016525093A (ja) 2016-08-22
EP3019477A1 (en) 2016-05-18
CN105358532A (zh) 2016-02-24
WO2015003223A1 (en) 2015-01-15
PT3019477T (pt) 2021-08-20
PL3019477T3 (pl) 2021-11-22
EP3019477A4 (en) 2017-01-11
US20160145213A1 (en) 2016-05-26
JP6505682B2 (ja) 2019-04-24
NZ630908A (en) 2017-08-25

Similar Documents

Publication Publication Date Title
US9714224B2 (en) Heterocyclic compounds and methods of their use
CN104470930B (zh) 杂环化合物和它们的使用方法
CN104470903B (zh) 杂环化合物和它们的使用方法
AU2013202982B2 (en) Heterocyclic compounds and methods for their use
AU2013202978A1 (en) Heterocyclic compounds and methods for their use
AU2013202973A1 (en) Heterocyclic compounds and methods for their use
EP1495017A2 (en) Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
CN107466293B (zh) 杂环化合物及其应用方法
HK1201531B (en) Heterocyclic compounds and methods for their use
HK1201533B (en) Heterocyclic compounds and methods for their use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190723